RAS inhibitor daraxonrasib demonstrates initial anti-tumor activity in pancreatic cancer
Daraxonrasib is an oral, multi-selective RAS inhibitor from Revolution Medicines
Data from this trial previously prompted the Food and Drug Administration (FDA) to grant orphan drug designation to daraxonrasib and the Phase 3 RASolute trial
Therapy is being investigated in pancreatic cancer because of the high prevalence of RAS mutations and lack of effective therapies
The targeted RAS inhibitor therapy daraxonrasib demonstrated the...
Scientists find blood-based biomarkers for inflammatory breast cancer
Inflammatory breast cancer (IBC) is highly aggressive, but there are no known genomic differences that can tell it apart from other breast cancers...
Researchers find biomarker of chemotherapy resistance in relapsed lung cancer
Standard chemotherapy treatment for small cell lung cancer (SCLC) often leads to resistance and eventual relapse
The YAP1 protein emerges in...
Tumor markers in rare appendiceal cancer may predict treatment outcomes
Researchers?monitored?levels of?common blood?markers?before and after surgery?to remove?cancer
Study found elevated?levels?of?CEA, CA19-9?and CA125?prior to surgery?were?strongly associated?with?poorer?outcomes
If levels?remained high?after surgery, patients?were?more likely to experience?recurrence?and?had?lower...
Researchers find potential one-two punch against triple-negative breast cancer
Many breast cancer therapies work by causing DNA replication stress, but triple-negative breast cancer (TNBC) cells survive this stress, even...